{"id":31190,"date":"2025-04-03T16:44:33","date_gmt":"2025-04-03T08:44:33","guid":{"rendered":"https:\/\/flcube.com\/?p=31190"},"modified":"2025-04-03T16:44:34","modified_gmt":"2025-04-03T08:44:34","slug":"biogens-biib080-receives-fda-fast-track-designation-for-alzheimers","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31190","title":{"rendered":"Biogen’s BIIB080 Receives FDA Fast Track Designation for Alzheimer’s"},"content":{"rendered":"\n

US-based Biogen Inc. (NASDAQ: BIIB<\/a>) announced that it has received Fast Track designation (FTD) from the US Food and Drug Administration (FDA) for BIIB080, its tau-targeted antisense oligonucleotide (ASO) therapy for Alzheimer\u2019s disease (AD). This designation underscores the potential of BIIB080 to address the significant unmet medical need in AD treatment.<\/p>\n\n\n\n

Collaboration and Licensing<\/strong>
Biogen secured an exclusive, royalty-bearing license to develop and commercialize BIIB080 worldwide through a license option agreement with Ionis Pharmaceuticals in 2019. This strategic partnership has enabled Biogen to advance the development of this innovative therapy.<\/p>\n\n\n\n

Clinical Development<\/strong>
BIIB080 is currently under investigation in the global Phase II CELIA study, focusing on patients with early-stage Alzheimer\u2019s disease. The therapy is designed to target microtubule-associated protein tau (MAPT) mRNA, reducing the production of tau protein, which is implicated in the pathogenesis of AD. Key data from this study are anticipated next year, potentially providing further insights into the efficacy and safety of BIIB080.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US-based Biogen Inc. (NASDAQ: BIIB) announced that it has received Fast Track designation (FTD) from…<\/p>\n","protected":false},"author":1,"featured_media":31191,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[351,993,64],"class_list":["post-31190","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-biogen","tag-nasdaq-biib","tag-rnai-aso"],"yoast_head":"\nBiogen's BIIB080 Receives FDA Fast Track Designation for Alzheimer's - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Biogen Inc. (NASDAQ: BIIB) announced that it has received Fast Track designation (FTD) from the US Food and Drug Administration (FDA) for BIIB080, its tau-targeted antisense oligonucleotide (ASO) therapy for Alzheimer\u2019s disease (AD). This designation underscores the potential of BIIB080 to address the significant unmet medical need in AD treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31190\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen's BIIB080 Receives FDA Fast Track Designation for Alzheimer's\" \/>\n<meta property=\"og:description\" content=\"US-based Biogen Inc. (NASDAQ: BIIB) announced that it has received Fast Track designation (FTD) from the US Food and Drug Administration (FDA) for BIIB080, its tau-targeted antisense oligonucleotide (ASO) therapy for Alzheimer\u2019s disease (AD). This designation underscores the potential of BIIB080 to address the significant unmet medical need in AD treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31190\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-03T08:44:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-03T08:44:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0306-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"598\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31190#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31190\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biogen’s BIIB080 Receives FDA Fast Track Designation for Alzheimer’s\",\"datePublished\":\"2025-04-03T08:44:33+00:00\",\"dateModified\":\"2025-04-03T08:44:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31190\"},\"wordCount\":172,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31190#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0306-png.webp\",\"keywords\":[\"Biogen\",\"NASDAQ: BIIB\",\"RNAi \\\/ ASO\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31190#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31190\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31190\",\"name\":\"Biogen's BIIB080 Receives FDA Fast Track Designation for Alzheimer's - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31190#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31190#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0306-png.webp\",\"datePublished\":\"2025-04-03T08:44:33+00:00\",\"dateModified\":\"2025-04-03T08:44:34+00:00\",\"description\":\"US-based Biogen Inc. (NASDAQ: BIIB) announced that it has received Fast Track designation (FTD) from the US Food and Drug Administration (FDA) for BIIB080, its tau-targeted antisense oligonucleotide (ASO) therapy for Alzheimer\u2019s disease (AD). This designation underscores the potential of BIIB080 to address the significant unmet medical need in AD treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31190#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31190\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31190#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0306-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0306-png.webp\",\"width\":1080,\"height\":598,\"caption\":\"Biogen's BIIB080 Receives FDA Fast Track Designation for Alzheimer's\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31190#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen’s BIIB080 Receives FDA Fast Track Designation for Alzheimer’s\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biogen's BIIB080 Receives FDA Fast Track Designation for Alzheimer's - Insight, China's Pharmaceutical Industry","description":"US-based Biogen Inc. (NASDAQ: BIIB) announced that it has received Fast Track designation (FTD) from the US Food and Drug Administration (FDA) for BIIB080, its tau-targeted antisense oligonucleotide (ASO) therapy for Alzheimer\u2019s disease (AD). This designation underscores the potential of BIIB080 to address the significant unmet medical need in AD treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31190","og_locale":"en_US","og_type":"article","og_title":"Biogen's BIIB080 Receives FDA Fast Track Designation for Alzheimer's","og_description":"US-based Biogen Inc. (NASDAQ: BIIB) announced that it has received Fast Track designation (FTD) from the US Food and Drug Administration (FDA) for BIIB080, its tau-targeted antisense oligonucleotide (ASO) therapy for Alzheimer\u2019s disease (AD). This designation underscores the potential of BIIB080 to address the significant unmet medical need in AD treatment.","og_url":"https:\/\/flcube.com\/?p=31190","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-03T08:44:33+00:00","article_modified_time":"2025-04-03T08:44:34+00:00","og_image":[{"width":1080,"height":598,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0306-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31190#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31190"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biogen’s BIIB080 Receives FDA Fast Track Designation for Alzheimer’s","datePublished":"2025-04-03T08:44:33+00:00","dateModified":"2025-04-03T08:44:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31190"},"wordCount":172,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31190#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0306-png.webp","keywords":["Biogen","NASDAQ: BIIB","RNAi \/ ASO"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31190#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31190","url":"https:\/\/flcube.com\/?p=31190","name":"Biogen's BIIB080 Receives FDA Fast Track Designation for Alzheimer's - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31190#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31190#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0306-png.webp","datePublished":"2025-04-03T08:44:33+00:00","dateModified":"2025-04-03T08:44:34+00:00","description":"US-based Biogen Inc. (NASDAQ: BIIB) announced that it has received Fast Track designation (FTD) from the US Food and Drug Administration (FDA) for BIIB080, its tau-targeted antisense oligonucleotide (ASO) therapy for Alzheimer\u2019s disease (AD). This designation underscores the potential of BIIB080 to address the significant unmet medical need in AD treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31190#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31190"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31190#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0306-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0306-png.webp","width":1080,"height":598,"caption":"Biogen's BIIB080 Receives FDA Fast Track Designation for Alzheimer's"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31190#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biogen’s BIIB080 Receives FDA Fast Track Designation for Alzheimer’s"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0306-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31190","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31190"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31190\/revisions"}],"predecessor-version":[{"id":31192,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31190\/revisions\/31192"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31191"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31190"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31190"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}